ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 5, 2006, Pages 955-962

  Feys, H B ^a   Liu, F ^b   Dong, N ^b   Pareyn, I ^a   Vauterin, S ^a   Vandeputte, N ^a   Noppe, W ^a   Ruan, C ^b   Deckmyn, H ^a   Vanhoorelbeke, Karen ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Monoclonal antibody; Normal human pooled plasma; Plasma exchange therapy; Thromboticthrombocytopenic purpura; Von Willebrand factor

Indexed keywords

ANTIGEN; MONOCLONAL ANTIBODY; RECOMBINANT ENZYME; RECOMBINANT VON WILLEBRAND FACTOR CLEAVING PROTEINASE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIGEN DETECTION; ARTICLE; BINDING COMPETITION; CAUCASIAN; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ENZYME BINDING; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS; AUTOANTIBODIES; BASE SEQUENCE; BLOTTING, WESTERN; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ETHNIC GROUPS; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 33645642908     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01833.x     Document Type: Article

References (39)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
2. Pimanda J, Hogg P. Control of von Willebrand factor multimer size and implications for disease. Blood Rev 2002; 16: 185.
3. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw Jr JD, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
4. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-63.
5. Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 2004; 41: 4-14.
6. Kokame K, Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 2004; 41: 34-40.
7. Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol 1996; 56: 191-207.
8. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
9. van der Straaten M, Jamart S, Wens R, Gottignies P, Dratwa M, Devriendt J. Treatment of thrombotic thrombocytopenic purpura. Intensive Care Med 2005; 31: 600.
10. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
11. Veyradier A, Girma JP. Assays of ADAMTS-13 activity. Semin Hematol 2004; 41: 41-7.
12. Tripodi A, Chantarangkul V, Bohm M, Budde U, Dong JF, Friedman KD, Galbusera M, Girma JP, Moake J, Rick ME, Studt JD, Turecek PL, Mannucci PM. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 1601-9.
13. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
14. Vetr H, Colle S, Geiter S, Zhegu Z, Scheifflinger F, Rieger M, Breitwieser A, Binder BR. TECHNOZYM ® ADAMTS 13 assays for analyzing the vWF cleaving protease ADAMTS 13. J Thromb Haemost 2005; 3 (Suppl. 1): P0875.
15. Masanori HY, Matsumoto M, Iwamoto T-A, Ishizachi H, Nishimura H, Isonishi Y, Soejima K, Nakagaki T, Mori T, Fujimura Y. Heightened proteolysis of plasma ADAMTS13 antigen in patients with thrombotic thrombocytopenic purpura. Blood (ASH Annual Meeting Abstracts) 2004; 104: 3946.
16. Rieger M, Ferrari S, Herzog A, Konetschny C, Dockal M, Plaimauer B, Scheiflinger F. Quantification of ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies by a newly developed sandwich ELISA. Blood (ASH Annual Meeting Abstracts) 2004; 104: 3946.
17. Gerritsen HE, Turecek PL, Schwarz HP, Lammle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF -A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 1386-9.
18. Zheng XL, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 2003; 278: 30136-41.
19. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
20. Kasinrerk W, Moonsom S, Chawansuntati K. Production of antibodies by single DNA immunization: Comparison of various immunization routes. Hybrid Hybridomics 2002; 21: 287-93.
21. Henke A. DNA immunization -a new chance in vaccine research ? Med Microbiol Immunol (Berl) 2002; 191: 187-90.
22. Anderson R, Gao XM, Papakonstantinopoulou A, Roberts M, Dougan G. Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin. Infect Immun 1996; 64: 3168-73.
23. Moonsom S, Khunkeawla P, Kasinrerk W. Production of polyclonal and monoclonal antibodies against CD54 molecules by intrasplenic immunization of plasmid DNA encoding CD54 protein. Immunol Lett 2001; 76: 25-30.
24. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-73.
25. Cauwenberghs N, Vanhoorelbeke K, Vauterin S, Westra DF, Romo G, Huizinga EG, Lopez JA, Berndt MC. Harsfalvi J, Deckmyn H, Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 2001; 98: 652-60.
26. Cauwenberghs N, Meiring M, Vauterin S, van WV, Lamprecht S, Roodt JP, Novak L, Harsfalvi J, Deckmyn H, Kotze HF. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 2000; 20: 1347-53.
27. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98: 1654-61.
28. Furlan M, Robles R, Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
29. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-4244.
30. Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005; 280: 21773-8.
31. Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V, Lonn E, Teo K, McQueen M, Yusuf S. C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol 2004; 24: 1509-15.
32. Forouhi NG, Rumley A, Lowe GD, McKeigue P, Sattar N. Specific elevation in plasma tissue plasminogen activator antigen concentrations in South Asians relative to Europeans. Blood Coagul Fibrinolysis 2003; 14: 755-60.
33. Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S. Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: An analysis of 1.2 million deaths. CMAJ 1999; 161: 132-8.
34. Yarranton H, Machin SJ. An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura. Curr Opin Neurol 2003; 16: 367-73.
35. Studt JD, Hovinga JA, Radonic R, Gasparovic V, Ivanovic D, Merkler M, Wirthmueller U, Dahinden C, Furlan M, Lammle B. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood 2004; 103: 4195-7.
36. Ashida A, Nakamura H, Yoden A, Tamai H, Ishizashi H, Yagi H, Matsumoto M, Fujimura Y. Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): important discrimination from Upshaw-Schulman syndrome. Am J Hematol 2002; 71: 318-22.
37. Klaus C, Plaimauer B, Studt JD, Dorner F, Lammle B, Mannucci PM, Scheiflinger F. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103: 4514-9.
38. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: A severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-3.
39. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.